Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents
Journal of Medicinal Chemistry2011Vol. 54(11), pp. 3839–3853
Citations Over TimeTop 10% of 2011 papers
Huiping Zhao, Alison C. Donnelly, Bhaskar Reddy Kusuma, Gary Brandt, Douglas Brown, Roger A. Rajewski, George Vielhauer, Jeffrey M. Holzbeierlein, Mark S. Cohen, Brian S. J. Blagg
Abstract
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ∼700-fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure-activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.
Related Papers
- → Alteration of Escherichia coli Topoisomerase IV to Novobiocin Resistance(2003)63 cited
- → GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin(1996)56 cited
- → Interplay of novobiocin-resistant and -sensitive DNA gyrase activities in self-protection of the novobiocin producer, Streptomyces sphaeroides(1989)45 cited
- → Elimination of plasmid pMG110 from Escherichia coli by novobiocin and other inhibitors of DNA gyrase(1984)43 cited
- → Discrepancy between the Antibacterial Activities and the Inhibitory Effects on <i>Micrococcus luteus</i> DNA Gyrase of 13 Quinolones(1986)19 cited